[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse RBSN

Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Lipid-anchor; Cytoplasmic side. Early endosome membrane Lipid-anchor. Note=Enriched in endosomes that are in close proximity to clathrin-enriched regions at the cell surface.
Domain PF01363 FYVE zinc finger
PF11464 Rabenosyn Rab binding domain
Function

Rab4/Rab5 effector protein acting in early endocytic membrane fusion and membrane trafficking of recycling endosomes. Required for endosome fusion either homotypically or with clathrin coated vesicles. Plays a role in the lysosomal trafficking of CTSD/cathepsin D from the Golgi to lysosomes. Also promotes the recycling of transferrin directly from early endosomes to the plasma membrane. Binds phospholipid vesicles containing phosphatidylinositol 3-phosphate (PtdInsP3) (PubMed:11062261, PubMed:11788822, PubMed:15020713). Plays a role in the recycling of transferrin receptor to the plasma membrane (PubMed:22308388).

> Gene Ontology
 
Biological Process GO:0000011 vacuole inheritance
GO:0006892 post-Golgi vesicle-mediated transport
GO:0006895 Golgi to endosome transport
GO:0006896 Golgi to vacuole transport
GO:0006906 vesicle fusion
GO:0007030 Golgi organization
GO:0007033 vacuole organization
GO:0007034 vacuolar transport
GO:0007041 lysosomal transport
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0016050 vesicle organization
GO:0016197 endosomal transport
GO:0016482 cytosolic transport
GO:0034058 endosomal vesicle fusion
GO:0034498 early endosome to Golgi transport
GO:0042147 retrograde transport, endosome to Golgi
GO:0044801 single-organism membrane fusion
GO:0048193 Golgi vesicle transport
GO:0048284 organelle fusion
GO:0048308 organelle inheritance
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0061025 membrane fusion
GO:0090160 Golgi to lysosome transport
GO:0090174 organelle membrane fusion
GO:1903358 regulation of Golgi organization
Molecular Function GO:0017016 Ras GTPase binding
GO:0017137 Rab GTPase binding
GO:0031267 small GTPase binding
GO:0051020 GTPase binding
Cellular Component GO:0005769 early endosome
GO:0010008 endosome membrane
GO:0010009 cytoplasmic side of endosome membrane
GO:0031901 early endosome membrane
GO:0044440 endosomal part
GO:0098552 side of membrane
GO:0098562 cytoplasmic side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168898: Toll-Like Receptors Cascades
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RBSN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RBSN in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RBSN in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91601
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 5901
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 4701
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0760.812
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.230.877
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0890.957
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2830.716
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4640.651
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2010.00114
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RBSN in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.8014.80.00448
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.8014.80.00826
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RBSN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RBSN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RBSN.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RBSN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RBSN expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RBSN and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRBSN
Namerabenosyn, RAB effector
Aliases Rabenosyn-5; ZFYVE20; zinc finger, FYVE domain containing 20; 110 kDa protein; FYVE finger-containing Rab5 e ......
Chromosomal Location3p25.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RBSN collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.